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Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with
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Background: Real time PCR has become the most common technique to monitor BCR-ABL transcript
levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL
levels of chronic myeloid leukemia patients treated with imatinib in the chronic phase and correlate
the response to therapy and event-free survival.
Methods: BCR-ABL levels were measured in peripheral blood cell samples using Real time PCR at
diagnosis and then every 3 months after starting therapy with imatinib. Major molecular response
was defined as a three-log reduction from the standardized baseline value. Major molecular response
values were adjusted to international scale using a conversion factor of 1.19. The results are reported
as a BCR-ABL/ABL ratio (%).
Results: Hematological, major cytogenetic and complete cytogenetic responses were achieved by 57
(95%), 45 (75%) and 38 (63%) patients, respectively. Twenty-four out of sixty patients achieved a
major molecular response (40%) in a median time of 8.5 months. Overall survival and event free
survival were higher for patients with (100%) versus patients without (77%) a complete cytogenetic
response (p-value = 0.01) at 48 months. Patients with complete cytogenetic response and major
molecular response had a higher event free survival compared to patients with complete cytogenetic
response but without major molecular response (p-value = 0.007).
Conclusion: In conclusion, the prognostic impact of achieving complete cytogenetic response and a
major molecular response and also the importance of molecular monitoring in the follow-up of
chronic myeloid leukemia patients were demonstrated.
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Introduction
Chronic myeloid leukemia (CML) is a hematopoietic disorder characterized by the
malignant expansion of bone marrow stem cells, with the presence of a reciprocal
translocation between chromosomes 9 and 22 resulting in the fusion gene, BCR-ABL,
whose product is a 210-kd protein with tyrosine kinase activity.(1)
The level of leukemic inhibition after treatment can be measured by quantitative
real-time PCR (RT-PCR), which has become the main molecular technique used to monitor
BCR-ABL transcript levels in CML during treatment with kinase inhibitors.(2-4) Increasing
levels of BCR-ABL are strongly predictive of cytogenetic and hematologic relapse after
allogeneic transplant.(5) Monitoring imatinib-treated CML patients by quantitative RT-PCR
has proved to be effective to define patient response as was reported in the IRIS trial.(6)
Attaining a major molecular response, defined as a three-log reduction in BCR-ABL levels
from the standardized baseline, is associated with a favorable progression-free survival(6-8)
and a longer duration of complete cytogenetic response (CCR).(9) Early reductions in BCR-
ABL can predict a subsequent cytogenetic response.(3)
Standardization of all procedures involved in BCR-ABL quantification is important
for the reproducibility and credibility of the results.
The aim of this study was to standardize RT-PCR in monitoring BCR-ABL levels in
CML patients treated with tyrosine kinase inhibitors and correlate BCR-ABL levels with
cytogenetic response, and event free and overall survival (OS).
Methods
Peripheral blood samples were collected from 60 patients with diagnosis of chronic
phase CML from June 2005 until September 2008. Diagnosis of CML was determined by
the presence of the Ph chromosome in cytogenetic evaluation and/or BCR-ABL transcripts
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by RT-PCR. Eligibility criteria included age of 18 years or
more. Patients provided written informed consent and the
study was approved by the local Research Ethics Committee.
The median follow-up time was 22 months (Range: 0.9 - 44.6
months).
Treatment procedures and definitions: patients
received imatinib as first or second line therapy (53 and 7
patients, respectively) for chronic phase CML. Four
patients participating in the TOPS trial were initially treated
with imatinib 800 mg/day and another 56 patients were
treated with imatinib 400 mg/day. Filgrastin 300 µg/day
was given if the neutrophil count was below 1.00 x 109/L
until recovery. Imatinib dose was escalated to 600 mg/day
when a patient had sub-optimal response [less than major
cytogenetic response (MCyR) at six months, less than CCR
at 12 months, less than major molecular response at 18
months] or failure (no minimal cytogenetic response at six
months, no MCyR at 12 months, loss of hematological
response, progression to accelerated phase or blast crisis
at any time) and was able to tolerate the increased dose.
Second generation tyrosine kinase inhibitors (TKI) (nilotinib
or dasatinib) were used for intolerance or resistance to
imatinib.
The second generation TKI were available in our
center only in clinical trials until 2008 when dasatinib
was approved in Brazil. Blood cell counts were performed
every two weeks until complete hematological response
was achieved,  then every one to three months.
Cytogenetic evaluation was performed at diagnosis and
then every 3-6 months until CCR was confirmed and then
every 6-12 months. Peripheral blood samples were
collected for the evaluation of BCR-ABL levels at
diagnosis and then every three months after starting
imatinib treatment. Criteria by the European Leukemia Net
group were used to define response: complete hematologic
response: normalization of blood cell counts with no
immature cells, < 5% of basophils, no palpable spleen;
cytogenetic response: partial cytogenetic response 1-35%
of Ph+ metaphases; CCR: 0% of Ph+ metaphases; major
molecular response: 3 or more log reduction of BCR-ABL
transcript levels of a standardized baseline (< 0.1 in the
international scale).(10)  The standard procedures described
by Brandford et al. 2006 and Hughes 2006(11,12) were
followed.
RNA extraction and cDNA synthesis
Total leukocyte RNA was extracted from 16 mL of
peripheral blood in tubes with EDTA. Samples were kept
at room temperature and processed within 24 h after
collection to avoid RNA degradation. Red cells were lysed
and residual cells were homogenized in 1 mL Trizol RNA
stabilization solution (Invitrogen®) and stored at -80°C.
RNA was extracted according to manufacturer´s
instructions. RNA integrity was assessed by
electrophoresis in agarose gel and quantified by Nanodrop
spectrophotometry (ND 1000-NanoDrop® 3.2.1).
SuperScript II (Invitrogen®) reverse transcriptase was
used for cDNA synthesis using 1 µg of total RNA and
random hexamers.
Quantitative real-time PCR
cDNA was amplified by 50 cycles of RT-PCR using
the ABI 7300 sequence detection system (Applied
biosystems) and TAQMAN Universal Master Mix in
accordance with the manufacturer's instructions in a final
reaction volume of 15 µL. ABL was used as the control
gene. The primers used were as followed:
– Forward (ABL-146F): 5'-GATACGAAGGGAGGG
TGTACCA-3';
– Reverse (ABL-240R): 5'-CTCGGCCAGGGTGTTGAA-3'
The bcr-abl and abl probes were dual labeled with a
reporter fluorochrome (FAM) and a quencher fluorochrome
(TAMRA). Probe and primer concentrations were 5 µM.
A standard curve was generated using serial dilutions
of a linearized plasmid containing a BCR-ABL insert (4-6
dilutions). Triplicates were performed for standard curves
and patients. The threshold was adjusted to 0.05. The
accepted coefficient to determine the standard curve (R2)
was close to 1.0 (greater than 99%). Slopes were considered
acceptable if the values were between 3.3 and 3.6. Quality
controls at high and low levels were used in each assay
(K562 lineage and a 3 log reduction sample). Negative
controls: no template and HL60 lineage.
The results were reported as a BCR-ABL/ABL ratio
(%). A baseline value for the laboratory was calculated using
the median quantification of 30 pre-treatment samples. The
standardized baseline value determined for our laboratory
was 83.67%. Major molecular response (MMR) was
considered a three log reduction from this baseline value.
MMR values were adjusted to international scale using a
conversion factor of 1.19.
Statistical analysis
The cutoff date for this analysis was April 2009. We
performed analyses of OS and progression free survival
(PFS), using the Kaplan-Meier method according to an
"intention to treat" basis. Differences between subgroups
receiving imatinib were calculated by the log-rank test and
a p-value < 0.05 was considered significant. OS was
measured from the beginning of imatinib treatment to the
date of death or last follow-up. Event-free Survival included
all patients and was calculated from beginning of imatinib
treatment until any event (death, progression to accelerated
phase or blast crisis CML, loss of CHR or CCyR). The
prognostic scores were calculated according to the method
of Sokal et al.(13) The analyses were performed using the
SPSS software, version 14.0.
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Results
Sixty CML patients in the chronic phase at diagnosis
were analyzed. Patients' characteristics are described in
Table 1. Imatinib was initiated in a median time of two
months from diagnosis (0.5-18.5 months). Hydrea was used
as cytoreduction therapy before imatinib until confirmation
of diagnosis of CML or imatinib availability. Imatinib was
initiated in early chronic phase (before 6 months from
diagnosis) in 57 patients and in the late chronic phase in
three patients (6, 8 and 18 months). Patients were treated
with imatinib for a median time of 22 months (Range: 0.9-44.6
months). Imatinib was used as first line treatment in 53 patients
(88.6%). Initial dose was 400 mg/day with the exception of
four patients participating from the TOPS trial(13) who were
treated with 800 mg/day up front.
Responses
Cumulative response rates: 57 (95%) patients achieved
complete hematologic response (CHR) in a median time of 21
days (Range: 0 - 147 days). One patient was primarily resistant
and two were intolerant with grade 3 hepatic toxicity; imatinib
was then discontinued. Forty-five (75%) patients achieved a
MCyR and 38 (63%) a CCR in a median time of 8 months
(Range: 3.4 - 29 months). In three patients cytogenetic
response could not be evaluated: one due to insufficient
number of metaphases for analysis and two were Ph negative
at diagnosis. In the group that achieved CCR, four patients
lost response: one is currently on Hydrea, one on dasatinib
and two are on imatinib 600 mg. None of them have achieved
MMR, so far.
Twenty-four out of 60 patients achieved a MMR (40%)
in a median time of 8.5 months (Range: 0.4-31 months). There
was a good correlation between CCR and MMR (p-value =
0.04). Overall and event free survival for all patients was 96%
and 77%, respectively at 48 months (Figure 1). OS and EFS
was higher for patients with CCR (100%) versus patients
with no CCR (77%; p-value = 0.01 – Figure 2).
Figure 2 – Overall Survival by cytogenetic and molecular responses
CCR = Complete Cytogenetic Response
MMR = Major Molecular Response
CHR = Complete Hematological Response
Figure 1 – Overall Survival and Event Free Survival of CML patients
in chronic phase
EFS = Event Free Survival
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Patients with CCR and MMR had a higher EFS in
comparison with patients with CCR and no MMR (p-value =
0.007) (Figure 3). There was no significant difference in
survival according to Sokal groups (Figure 4) although
intermediate and high scores had more events.
Three patients progressed: one to blast crisis, one to
accelerated phase and one to lost hematological response in
chronic phase. Median time to progression was 13.5 months.
Imatinib was discontinued in ten of sixty patients
(16.6%): six (10%) due to intolerance (hepatic toxicity grade
3 in three patients; hematological toxicity grade 4 in three
patients) and four (6.6%) due to resistance. The three patients
with hepatic toxicity are currently on nilotinib. All achieved
major cytogenetic response and two of them major molecular
response. Patients who discontinued imatinib due to
hematological toxicity were treated with dasatinib. One of
them progressed to blast crisis and died of disease
progression. Four patients discontinued imatinib due to
resistance: one lost cytogenetic response and had T315I
mutation, two had cytogenetic resistance and one progressed
to accelerated phase. This last patient had the M244V
mutation identified and died due to disease progression. The
two patients with cytogenetic resistance are alive: one
received hematopoietic stem cell transplantation and is in
complete molecular response and the other one is in major
cytogenetic response with dasatinib. So, during imatinib
treatment only two patients died, one due to progression
and the other due to causes not related to CML.
Discussion
In this study we monitored CML patients treated with
imatinib in the chronic phase by RT-PCR. Samples were
collected at diagnosis and then every three months after
starting imatinib therapy.
Initially we performed the standardization of BCR-ABL
quantification by RT-PCR. The standardization involved a
series of procedures, such as appropriate sample collection,
RNA extraction, cDNA synthesis, choice of control gene
(ABL), equipment, standard curves of control gene and BCR-
ABL and RT-PCR analysis. The recommendations for
standardizing BCR-ABL measurement were reviewed by
Hughes et al. in 2006.(11) Many of the procedures discussed
in that study were used to standardize the procedures in our
laboratory. Recently Branford et al. validated the use of an
international scale to report PCR results which allows a
comparison of molecular response rates between different
laboratories.(14) Standardization is an important step to
compare treatment in different populations. We calculated
the laboratory baseline based on the median value of
quantification of 30 CML samples at diagnosis. We found a
good correlation between cytogenetic and molecular response
as previously described.(4)
A significant proportion of patients achieved CCR and
MMR (63% and 40%, respectively). In general, after 12
months of imatinib therapy, 69% of patients with CML in
chronic phase achieved CCR, as described in IRIS study.(15)
Among patients with CCR after 12 months of imatinib
treatment, those with MMR have a significantly improved
progression-free survival compared to those without
MMR.(6) In our study, OS and EFS was higher for patients
with CCR (100%) versus patients with no CCR (77%). We
also observed that patients presenting CCR and MMR had
a better event free survival compared to patients with CCR
but no MMR (100% vs. 60%). The rate of progression was
higher in patients who did not achieve MMR. In fact,
patients who achieved MMR did not progress during the
follow-up. Iacobucci et al. showed that attaining MMR at
the time of first CCR is associated with longer cytogenetic
Machado MP, Tomaz JP, Lorand-Metze I, de Souza CA, Vigorito AC, Delamain MT, et al.
Figure 3 – Event Free Survival Complete Cytogenetic Response Group
MMR = Major Molecular Response
Figure 4 –  Event Free Survival by Sokal
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remission compared to not achieving MMR.(9) Moreover,
patients with a BCR-ABL ratio > 10% after three months on
imatinib had a 92% of probability of CCR, but the risk of
progression was almost 3-fold that of patients with a ratio <
1%, suggesting that patients not in CCR in the first year have
a higher risk of progression. Similar results were found by
Marin et al. who showed that patients with CCR but no MMR
at 12 or 18 months were more likely to lose CCR than patients
that achieved MMR (23.6% vs. 2.6% and (24.4% vs. 0%,
respectively). However, they did not find any significant
difference in OS or PFS in patients without MMR at 12 or 18
months.(16)
In summary, this study demonstrates that RT-PCR is an
accurate and practical method to monitor BCR-ABL
transcripts, that correlates well with clinical response.
Attainment of MMR is an important goal in the treatment of
CML and was related to a better EFS.
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